I am a
Home I AM A Search Login

Papers of the Week

2020 Mar 09

J Hepatol

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.


Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, Shapiro D, Bowlus CL
J Hepatol. 2020 Mar 09.
PMID: 32165251.


Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC.